Investment thesis for Mind Medicine -Psychedelic inspired medicines

Summary

• MindMed a neuro-pharmaceutical company, discovers, develops, and deploys psychedelic inspired medicines to improve health, promote wellness, and alleviate suffering.
• The company is primarily focusing on developing a non-hallucinogenic version of the psychedelic ibogaine to address the opioid crisis.
• MindMed has initiated or is initiating studies to evaluate potential treatments to help patients with adult attention deficit/hyperactivity disorder (ADHD), anxiety, cluster headaches, and substance abuse.

There are 5 tailwinds that I believe will cause mindmed to be the Category leader

• As COVID-19 continues to compound society’s prevalence of anxiety disorders globally, MindMed is pushing ahead with full vigor on the planning and design of Project Lucy.”
• A Blue Cross Blue Shield report from 2019 found that millennials are seeing their physical and mental health decline at a faster rate than Gen X as they age. Without proper management or treatment, millennials could see a 40% uptick in mortality compared with Gen Xers of the same age, the report found.
• The stigma for mental health and wellness. is no longer a barrier as millennials embrace mindfulness. and are open to experimentation with Psychedelics and other Nutraceuticals.
• The movement to decriminalize psilocybin in the United States will open the door for safety and efficacy data coupled with legal reforms generating broader interest in the medical and therapeutic promise of psychedelics, with a growing crop of mainstream media outlets now covering developments.
• A successful. acceptance of the NASDAQ up-listing could serve as another major catalyst for institutional investor and analyst coverage.

Qualitative

MindMed will become the category leader in psychedelic inspired medicines. in collaboration with University Hospital Basel’s Liechti Laboratory, has discovered and filed a patent application in the United States (preserving all worldwide rights) for a neutralizer technology intended to shorten and stop the effects of an LSD trip during a therapy session. This discovery, when further developed, may act as the ‘off-switch’ to an LSD trip.

• One of the many fears and stigmas associated with psychedelics are rare occurrences of ‘bad trips’. MindMed is equipping therapists and other medical professionals with the resources and technology to better control the effects of dosing LSD in a clinical setting to improve the patient experience and patient outcomes.
• This advancement paves the way for greater therapeutic applications of LSD and shorter-acting psychedelic therapy treatments. MindMed believes this technology, when further developed, may one day be marketed as an added feature to shorten a therapy session and stop a session if the patient is not comfortable.
• The next decade will lead to further breakthroughs and innovation in personalized medicine MindMed, working with the Liechti Laboratory, will continue to research and build a patent portfolio around psychedelic compounds that create novel approaches to medicine.
• MindMed will initially focus on the opioid crisis: in the USA, it is estimated that there are at least 11 million people misusing opioids, with an annual cost to the US economy of an estimated $500 billion. Existing addiction treatments have been inadequate, and the FDA has provided incentives for effective opioid treatments, including accelerated approval and “breakthrough” designation for the development of treatments for opioid use disorders, and a lowered threshold for approval — accepting a standard of fewer occasions per day. MindMed intends to leverage and develop its existing intellectual property in treating opioid use disorder, in particular its 18-MC molecule, which is a synthetic congener of the ibogaine plant, and which has been proven effective in the past for treating addictions. In early tests, 18-MC appears to have retained these anti- addictive properties while eliminating the downsides of ibogaine use, including a risk of cardiac toxicity, a lengthy hallucinogenic experience, and being a banned substance.

Quantitive

On July 28, 2020, MindMed concluded dosing in a Phase 1 Single Ascending Dose (SAD) study of 18-MC. The dosing of 18-MC was well tolerated in humans and will help advance planning for a Phase 2a clinical trial in opioid addiction. Further, the study has not incurred any delays due to the COVID-19 pandemic and the Multiple Ascending Dose (MAD) study is on track according to the original development timeline. MindMed plans to begin the Phase 2a study of 18-MC in opioid addiction by the end of this year.

MindMed will pursue N-N-Dimethyltryptamine (DMT), the principally active ingredient in Ayahuasca. MindMed is providing startup funding for a Phase 1 clinical trial testing various intravenous dosing regimens of DMT, expected to begin in Q4 of 2020.

Disclosure long mindmed .

Disclaimer this is not investment advice and is for research purposes only . Consult a registered investment advisor before making any investment.